Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

Elon Musk, 53, admitted to taking Mounjaro, a drug that typically treats type-2 diabetes by lowering a person's blood sugar ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product ...

Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...